Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (41-50 of 101) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|April 3, 2024
Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutationsAlesia A Khan, Daniel James, Vibeke Andresen, et al.
Blood|November 16, 2020
SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcomeClaire Schwab, Kathryn Roberts, Judith M Boer, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 MutationsSylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Cancer Cell|October 31, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
The Lancet. Oncology|October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines CommitteeJaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Cancer Cell|December 15, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
British Journal of Haematology|May 21, 2025
Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programmeHenry Wood, Jenny O'Nions, Wei Yee Chan, et al.
Blood Advances|September 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AMLNigel Russell, Jad Othman, Oliver Cumming, et al.
Pageof 11

Showing results (41-50 of 101) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|April 3, 2024
Pre-B acute lymphoblastic leukemia presenting with NPM1 and FLT3 mutationsAlesia A Khan, Daniel James, Vibeke Andresen, et al.
Blood|November 16, 2020
SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcomeClaire Schwab, Kathryn Roberts, Judith M Boer, et al.
British Journal of Haematology|December 27, 2021
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemiaThomas Coats, Daniel Bean, Aymeric Basset, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 MutationsSylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Cancer Cell|October 31, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
The Lancet. Oncology|October 30, 2025
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines CommitteeJaime Sanz, Gesine Bug, Fabio Ciceri, et al.
Cancer Cell|December 15, 2021
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipientsPatrick Harrington, Katie J Doores, Chandan Saha, et al.
Blood Advances|April 14, 2023
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDSJustin Loke, Nicholas McCarthy, Aimee Jackson, et al.
British Journal of Haematology|May 21, 2025
Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programmeHenry Wood, Jenny O'Nions, Wei Yee Chan, et al.
Blood Advances|September 30, 2025
Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AMLNigel Russell, Jad Othman, Oliver Cumming, et al.
Pageof 11